ReviewInternational journal of nanomedicine2026
Research Progress on Nanoformulations Based on Active Components from Traditional Chinese Medicine for MASLD.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease with rising prevalence and disease burden. However, despite recent therapeutic advances, effective and broadly applicable treatment options remain limited, prompting continued efforts to develop novel therapeutic agents. Traditional Chinese Medicine (TCM) has attracted growing interest in MASLD management because its bioactive compounds can target multiple pathogenic processes. However, many TCM-derived compounds are limited by poor solubility, low bioavailability, and insufficient tissue specificity. Nanotechnology-based formulations enable controlled release and targeted delivery, offering a strategy to improve the utilization and therapeutic efficacy of TCM-derived active ingredients against MASLD. Based on a structured literature search across four databases, 45 representative studies were included and narratively synthesized according to nanoplatform type, design features, and mechanism-related therapeutic actions. Compared with previous broader reviews on TCM nanomedicine or MASLD-related nanotherapies, this review particularly emphasizes MASLD-oriented TCM nanoformulations from the perspectives of platform classification, design features, and mechanism-related therapeutic actions. We also discuss current challenges and future directions for clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.